Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof

A compound of the formula (I):

• wherein:
• A is a member selected from the group consisting of:
• benzene, thiophene, furan, pyrrole, indole,
• wherein
• each B is independently selected from the group consisting of —C(—R1)(—R2)—, —O— and —N(—J—R3)—, wherein not more than one B in any ring is either —O— or —N(—J—R3)—;
• each m is independently an integer from 0 to 4;
• each n is independently an integer from 1 to 4;
• each q is independently an integer from 0 to 8;
• Y is a member selected from the group consisting of —(CH2)q—, —(CH2)mO— and —(CH2)m—N(—J1—)—R4;
• Z is a member selected from the group consisting of —(CH2)n—C(═O)—NHOH, —(CH2)nCOOH, —(CH2)nCOOMe and —(CH2)nCOOEt;
• L is a member selected from the group consisting of —(CH2)q—, —(CH2)mO— and —(CH2)m—N—(—J2—)—R5;
• J, J1 and J2 are each independently selected from the group consisting of C(═O) and a bond;
• R1 is a member selected from the group consisting of H, —N(—J3—R6)(—J4—R7) and —O—J5—R8, wherein J3, J4 and J5 are each independently selected from the group consisting of —C(═O)— and a bond, wherein at least one of J3 and J4 is a bond;
• R2 is a member selected from the group consisting of H, —N(—J6—R9)(—J7—R10) and —O—J8—R11, wherein J6, J7 and J8 are independently selected from the group consisting of —C(═O)— and a bond, wherein at least one of J6 and J7 is a bond;
• R3 is a member selected from the group consisting of H, C1-C8 alkyl, CF3 and O—R12;
• R4 is a member selected from the group consisting of H, C1-C8 alkyl, CF3 and O—R13;
• R5 is a member selected from the group consisting of H, C1-C8 alkyl, CF3 and O—R14;
• R6 is a member selected from the group consisting of H, C1-C8 alkyl, CF3 and O—R15;
• R7 is a member selected from the group consisting of H, C1-C8 alkyl, CF3 and O—R16;
• R8 is a member selected from the group consisting of H, C1-C8 alkyl, CF3 and O—R17;
• R9 is a member selected from the group consisting of H, C1-C8 alkyl, CF3 and O—R18;
• R10 is a member selected from the group consisting of H, C1-C8 alkyl, CF3 and O—R19;
• R11 is a member selected from the group consisting of H, C1-C8 alkyl, CF3 and O—R20;
• R12, R13, R14, R15, R16, R17, R18, R19 and R20 are each independently selected from the group consisting of C1-C4 alkyl, cycloalkyl and benzyl;
• and all pharmaceutically acceptable stereoisomers, and prodrugs thereof.